These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 7471114)

  • 1. Phase I study of 6-diazo-5-oxo-L-norleucine (DON).
    Sklaroff RB; Casper ES; Magill GB; Young CW
    Cancer Treat Rep; 1980; 64(12):1247-51. PubMed ID: 7471114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II evaluation of DON (6-diazo-5-oxo-L-norleucine) in patients with advanced colorectal carcinoma.
    Lynch G; Kemeny N; Casper E
    Am J Clin Oncol; 1982 Oct; 5(5):541-3. PubMed ID: 7180833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial of 6-diazo-5-oxo-L-norleucine (DON) administered by 5-day courses.
    Earhart RH; Koeller JM; Davis HL
    Cancer Treat Rep; 1982 May; 66(5):1215-7. PubMed ID: 7083223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I and pharmacokinetic studies of DON.
    Kovach JS; Eagan RT; Powis G; Rubin J; Creagan ET; Moertel CG
    Cancer Treat Rep; 1981; 65(11-12):1031-6. PubMed ID: 7296548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I clinical study of dihydroxyanthracenedione administered on a 5-day iv schedule.
    Valdivieso M; Bedikian AY; Burgess MA; Savaraj N; Jeffers WB; Bodey GP
    Cancer Treat Rep; 1981; 65(9-10):841-4. PubMed ID: 7273017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II study of 6-diazo-5-oxo-L-norleucine (DON, NSC-7365) in advanced large bowel carcinoma.
    Rubin J; Sorensen S; Schutt AJ; van Hazel GA; O'Connell MJ; Moertel CG
    Am J Clin Oncol; 1983 Jun; 6(3):325-6. PubMed ID: 6846250
    [No Abstract]   [Full Text] [Related]  

  • 7. Phase I study on bruceantin administered on a weekly schedule.
    Liesmann J; Belt RJ; Haas CD; Hoogstraten B
    Cancer Treat Rep; 1981; 65(9-10):883-5. PubMed ID: 7273023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic and phase I study of intravenous DON (6-diazo-5-oxo-L-norleucine) in children.
    Sullivan MP; Nelson JA; Feldman S; Van Nguyen B
    Cancer Chemother Pharmacol; 1988; 21(1):78-84. PubMed ID: 3342470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study on DON in patients with previously treated advanced lung cancer.
    Eagan RT; Frytak S; Nichols WC; Creagan ET; Ingle JN
    Cancer Treat Rep; 1982 Aug; 66(8):1665-6. PubMed ID: 6286122
    [No Abstract]   [Full Text] [Related]  

  • 10. Phase I clinical evaluation of 9,10-anthracenedicarboxyaldehyde[bis(4,5-dihydro-1H-imidazol-2-yl)hydrazone]dihydrochloride (bisantrene).
    Yap BS; Yap HY; Blumenschein GR; Bedikian AY; Pocelinko R; Bodey GP
    Cancer Treat Rep; 1982 Jul; 66(7):1517-20. PubMed ID: 7093967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
    Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
    Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paclitaxel in the treatment of patients with upper gastrointestinal carcinomas.
    Ajani JA; Ilson DH; Kelsen DP
    Semin Oncol; 1996 Oct; 23(5 Suppl 12):55-8. PubMed ID: 8941411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I evaluation of IMPY in a twice weekly schedule.
    Haas CD; Joseph U; Belt RJ; Hoogstraten B
    Cancer Treat Rep; 1981; 65(5-6):439-41. PubMed ID: 7237464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
    Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J
    Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II evaluation of dianhydrogalactitol in advanced head and neck carcinomas.
    Edmonson JH; Frytak S; Letendre L; Kvols LK; Eagan RT
    Cancer Treat Rep; 1979; 63(11-12):2081-3. PubMed ID: 526941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of cis-dichlorodiammineplatinum(II) (NSC-119875) in advanced adenocarcinoma of the ovary.
    Wiltshaw E; Kroner T
    Cancer Treat Rep; 1976 Jan; 60(1):55-60. PubMed ID: 1000519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I clinical trial of mitozolomide.
    Newlands ES; Blackledge G; Slack JA; Goddard C; Brindley CJ; Holden L; Stevens MF
    Cancer Treat Rep; 1985; 69(7-8):801-5. PubMed ID: 4016790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of tricyclic nucleoside phosphate.
    Mittelman A; Casper ES; Godwin TA; Cassidy C; Young CW
    Cancer Treat Rep; 1983 Feb; 67(2):159-62. PubMed ID: 6825123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of paclitaxel and cisplatin in patients with non-small cell lung cancer.
    von Pawel J; Wagner H; Niederle N; Heider A; Koschel G; Hecker D; Hanske M
    Semin Oncol; 1996 Dec; 23(6 Suppl 16):47-50. PubMed ID: 9007121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I study of aziridinylbenzoquinone (NSC 182986).
    Bedikian AY; Bodey GP; Burgess MA; Freireich EJ
    Cancer Clin Trials; 1981; 4(4):459-63. PubMed ID: 7318128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.